UNSPSC 51331607: Pentiapine maleate

This classification denotes a dopamine antagonist with the molecular formula C15H17N5S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z5P36MQ43L, chemically known as 5-(4-methyl-1-piperazinyl)imidazo(2,1-b)(1,3,5)benzothiadiazepine maleate (1:1) but more generally known as pentiapine maleate, which bears US NIH Compound Identifier 6435401. Most nations, for tariff and trade purposes, schedule pentiapine maleate under HS 29349990 and SITC 51579. As of Q4 2014, PENTIAPINE MALEATE remains US FDA's Preferred Term for this commodity.

Pentiapine maleate bears US NLM identifiers UMLS ID C0055211 and NCI Concept Code C90844. SMILES: CN1CCN(CC1)C2=NC3CCCCC3SC4N2CCN4.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51331607 Pentiapine maleate is a Commodity code, but the recent state and local opportunities tagged under it do not reflect procurement of this specific pharmaceutical. Instead, the code shows activity for broader pharmaceutical and over-the-counter product sourcing, including naloxone, generic multi-source medications, and direct-to-manufacturer prescription programs that state health and human services agencies are using to support community health initiatives, pharmacy benefit management, and emergency response capabilities. The work being solicited spans competitive bidding for specific pharmaceutical inventories, cooperative purchasing agreements for generic drugs across multiple jurisdictions, and exploratory vendor outreach for alternative pharmacy supply models that bypass traditional pharmacy benefit managers and group purchasing organizations.

Activity comes from state health departments and cooperative purchasing alliances, primarily in Florida, Minnesota (serving multi-state participant networks including Oregon), and Texas, with responses due between April and July 2026. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response deadline July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local facilities; and the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. The MMCAP RFP specifies contract terms through June 30, 2028 with potential extensions, mandatory compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and pricing weighted 75 percent on competitiveness. Vendors bidding on these opportunities must meet E-Verify requirements, maintain specified insurance coverage including commercial general liability and professional liability, and supply products with FDA compliance and minimum shelf-life specifications.